GSK and Ionis announced positive topline results from two pivotal Phase 3 studies, B‑Well 1 and B‑Well 2, evaluating bepirovirsen, an antisense oligonucleotide for chronic hepatitis B. The trials enrolled more than 1,800 patients across 29 countries and demonstrated safety and efficacy endpoints that GSK says support a regulatory submission strategy. Bepirovirsen is positioned as a potential "functional cure" for chronic hepatitis B, a high‑unmet‑need area, and GSK plans to use the Phase 3 dataset to press toward regulatory approvals. The program was originally licensed from Ionis, which retains partner status under the collaboration. Positive Phase 3 readouts for a functional‑cure candidate could reshape HBV standard of care and spur competitor programs focused on viral suppression and immune restoration.